Combivent Respimat is owned by Boehringer Ingelheim.
Combivent Respimat contains Albuterol Sulfate; Ipratropium Bromide.
Combivent Respimat has a total of 6 drug patents out of which 0 drug patents have expired.
Combivent Respimat was authorised for market use on 07 October, 2011.
Combivent Respimat is available in spray, metered;inhalation dosage forms.
The generics of Combivent Respimat are possible to be released after 16 October, 2030.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7284474 | BOEHRINGER INGELHEIM | Piston-pumping system having o-ring seal properties |
Aug, 2024
(1 year, 2 months from now) | |
US7896264 | BOEHRINGER INGELHEIM | Microstructured high pressure nozzle with built-in filter function |
May, 2025
(1 year, 11 months from now) | |
US7396341 | BOEHRINGER INGELHEIM | Blocking device for a locking stressing mechanism having a spring-actuated output drive device |
Oct, 2026
(3 years from now) | |
US9027967 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2027
(3 years from now) | |
US7837235 | BOEHRINGER INGELHEIM | Device for clamping a fluidic component |
Mar, 2028
(4 years from now) | |
US8733341 | BOEHRINGER INGELHEIM | Atomizer and method of atomizing fluid with a nozzle rinsing mechanism |
Oct, 2030
(7 years from now) |
Drugs and Companies using ALBUTEROL SULFATE; IPRATROPIUM BROMIDE ingredient
Market Authorisation Date: 07 October, 2011
Treatment: NA
Dosage: SPRAY, METERED;INHALATION
12
European Union
9
United States
9
Germany
6
Japan
5
Spain
5
Canada
4
Austria
4
Denmark
4
Australia
3
Poland
3
China
3
Brazil
3
Korea, Republic of
3
Cyprus
3
Portugal
3
Mexico
3
South Africa
3
Colombia
3
Slovenia
2
Uruguay
2
Hong Kong
2
Ukraine
2
Argentina
2
EA
2
Norway
2
New Zealand
2
Croatia
2
Peru
2
Taiwan
2
Ecuador
1
Malaysia
1
RS
1
Russia
1
Yugoslavia
1
ME
1
Israel
1
Egypt
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic